157 related articles for article (PubMed ID: 22166404)
1. Vaccination for Parkinson's disease.
Schneeberger A; Mandler M; Mattner F; Schmidt W
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S11-3. PubMed ID: 22166404
[TBL] [Abstract][Full Text] [Related]
2. Sticking it to Parkinson's disease.
Leslie M
Sci Aging Knowledge Environ; 2005 Jun; 2005(25):nf46. PubMed ID: 15975896
[No Abstract] [Full Text] [Related]
3. AFFITOME® technology in neurodegenerative diseases: the doubling advantage.
Schneeberger A; Mandler M; Mattner F; Schmidt W
Hum Vaccin; 2010 Nov; 6(11):948-52. PubMed ID: 20980801
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein, Parkinson's disease, and Alzheimer's disease.
Kim S; Seo JH; Suh YH
Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S9-13. PubMed ID: 15109581
[TBL] [Abstract][Full Text] [Related]
5. Polymer brain-nanotherapeutics for multipronged inhibition of microglial α-synuclein aggregation, activation, and neurotoxicity.
Bennett NK; Chmielowski R; Abdelhamid DS; Faig JJ; Francis N; Baum J; Pang ZP; Uhrich KE; Moghe PV
Biomaterials; 2016 Dec; 111():179-189. PubMed ID: 27736702
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.
Neff F; Wei X; Nölker C; Bacher M; Du Y; Dodel R
Autoimmun Rev; 2008 Jun; 7(6):501-7. PubMed ID: 18558370
[TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
8. Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease.
Zella MAS; Metzdorf J; Ostendorf F; Maass F; Muhlack S; Gold R; Haghikia A; Tönges L
Cells; 2019 Jan; 8(2):. PubMed ID: 30708997
[TBL] [Abstract][Full Text] [Related]
9. α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.
Chu Y; Mickiewicz AL; Kordower JH
Neurobiol Dis; 2011 Jan; 41(1):71-82. PubMed ID: 20816781
[TBL] [Abstract][Full Text] [Related]
10. Yeast reveals similar molecular mechanisms underlying alpha- and beta-synuclein toxicity.
Tenreiro S; Rosado-Ramos R; Gerhardt E; Favretto F; Magalhães F; Popova B; Becker S; Zweckstetter M; Braus GH; Outeiro TF
Hum Mol Genet; 2016 Jan; 25(2):275-90. PubMed ID: 26586132
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein in Parkinson's disease: a villain or tragic hero? A critical view of the formation of α-synuclein aggregates induced by dopamine metabolites and viral infection.
Carmo-Gonçalves P; Coelho-Cerqueira E; de Araujo Lima V; Follmer C
Expert Rev Neurother; 2023 Apr; 23(4):321-330. PubMed ID: 37016954
[TBL] [Abstract][Full Text] [Related]
12. Active immunization therapies for Parkinson's disease and multiple system atrophy.
Schneeberger A; Tierney L; Mandler M
Mov Disord; 2016 Feb; 31(2):214-24. PubMed ID: 26260853
[TBL] [Abstract][Full Text] [Related]
13. Inducible over-expression of wild type alpha-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death.
Vekrellis K; Xilouri M; Emmanouilidou E; Stefanis L
J Neurochem; 2009 Jun; 109(5):1348-62. PubMed ID: 19476547
[TBL] [Abstract][Full Text] [Related]
14. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
Rockenstein E; Crews L; Masliah E
Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
[TBL] [Abstract][Full Text] [Related]
15. Development of vaccination approaches for the treatment of neurological diseases.
Federoff HJ
J Comp Neurol; 2009 Jul; 515(1):4-14. PubMed ID: 19399901
[TBL] [Abstract][Full Text] [Related]
16. Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents.
Polinski NK; Volpicelli-Daley LA; Sortwell CE; Luk KC; Cremades N; Gottler LM; Froula J; Duffy MF; Lee VMY; Martinez TN; Dave KD
J Parkinsons Dis; 2018; 8(2):303-322. PubMed ID: 29400668
[TBL] [Abstract][Full Text] [Related]
17. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
Gallardo G; Schlüter OM; Südhof TC
Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
[TBL] [Abstract][Full Text] [Related]
18. Toxic Metamorphosis-How Changes from Lysosomal to Cytosolic pH Modify the Alpha-Synuclein Aggregation Pattern.
Eymsh B; Drobny A; Heyn TR; Xiang W; Lucius R; Schwarz K; Keppler JK; Zunke F; Arnold P
Biomacromolecules; 2020 Dec; 21(12):4673-4684. PubMed ID: 32986422
[TBL] [Abstract][Full Text] [Related]
19. Selective noradrenergic vulnerability in α-synuclein transgenic mice.
Sotiriou E; Vassilatis DK; Vila M; Stefanis L
Neurobiol Aging; 2010 Dec; 31(12):2103-14. PubMed ID: 19152986
[TBL] [Abstract][Full Text] [Related]
20. Influence of different promoters on the expression pattern of mutated human alpha-synuclein in transgenic mice.
Maskri L; Zhu X; Fritzen S; Kühn K; Ullmer C; Engels P; Andriske M; Stichel CC; Lübbert H
Neurodegener Dis; 2004; 1(6):255-65. PubMed ID: 16908976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
